好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impulse-Control Behaviors in Parkinson's Disease Are Not Dose-Dependent
Movement Disorders
P04 - (-)
194
BACKGROUND: Recent evidence suggests that DA therapy in PD is associated with the development of ICBs. However, there have been no studies which examine the effect of cumulative lifetime dose of DA on expression of ICBs.
DESIGN/METHODS: Participants were recruited from an academic Neurology practice, and were either enrolled in a clinical trial for DA, or identified as candidates to start therapy with a non-ergot DA. Subjects were interviewed using a semi-structured questionnaire assessing for ICBs at 6, 12, 18, and 24 months. Cumulative exposure to ropinirole or pramipexole was calculated using drug accountability logs. Levodopa-equivalent doses (LED) were used in an Analysis of Variance with repeated measures at 6 and 12 months after initiating DA.
RESULTS: Of 18 subjects starting agonist therapy, 9 were randomized to ropinerole and 9 to pramipexole. 8/18 (44%) subjects developed ICBs. There was no significant difference in cumulative doses administered between ropinirole and pramipexole when looking at LED equivalents. The overall cumulative dose of medication was not associated with expression of ICBs. There was no difference in expression of ICBs between pramipexole and ropinirole when looking at cumulative doses.
CONCLUSIONS: This is the first prospective study to examine the effect of cumulative lifetime exposure of DA on expression of ICBs. While ICB expression may be a class effect of non-ergot DA, these behaviors do not appear to be a dose-related, or medication-specific effect. Other characteristics, including disease-related and personality-dependent factors, may contribute to the expression of ICBs in PD. Early recognition of these characteristics before initiation of DA therapy can help guide prescribing practices.
Authors/Disclosures
Jennifer S. Hui, MD (University of Southern California)
PRESENTER 		Dr. Hui has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunovion. Dr. Hui has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. The institution of Dr. Hui has received research support from Roche. The institution of Dr. Hui has received research support from Abbvie. Dr. Hui has received personal compensation in the range of $500-$4,999 for serving as a Roundtable speaker with Medscape .
Laurice T. Yang, MD, MHA, FAAN The institution of Dr. Yang has received research support from Alzheimer's Disease Research Center (ADRC). The institution of Dr. Yang has received research support from Pacific Northwest Udall Center . The institution of Dr. Yang has received research support from Biogen/Parkinson's Study Group . The institution of Dr. Yang has received research support from Eli Lily . The institution of Dr. Yang has received research support from Michael J. Fox Foundation For Parkinson's Research . The institution of Dr. Yang has received research support from Sanofi . Dr. Yang has received personal compensation in the range of $500-$4,999 for serving as a Chair, Workgroup with 好色先生 .
No disclosure on file
Daniel M. Togasaki, MD, PhD (University of Southern California) No disclosure on file
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.